AU2001239052A1 - Compositions for prevention and treatment of dementia - Google Patents

Compositions for prevention and treatment of dementia

Info

Publication number
AU2001239052A1
AU2001239052A1 AU2001239052A AU3905201A AU2001239052A1 AU 2001239052 A1 AU2001239052 A1 AU 2001239052A1 AU 2001239052 A AU2001239052 A AU 2001239052A AU 3905201 A AU3905201 A AU 3905201A AU 2001239052 A1 AU2001239052 A1 AU 2001239052A1
Authority
AU
Australia
Prior art keywords
dementia
prevention
compositions
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001239052A
Inventor
Allen I. Bain
Alexander Zolotoy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Network Ltd
Original Assignee
Immune Network Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Network Ltd filed Critical Immune Network Ltd
Publication of AU2001239052A1 publication Critical patent/AU2001239052A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU2001239052A 2000-03-06 2001-03-05 Compositions for prevention and treatment of dementia Abandoned AU2001239052A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18731000P 2000-03-06 2000-03-06
US60187310 2000-03-06
PCT/CA2001/000271 WO2001066096A2 (en) 2000-03-06 2001-03-05 Compositions for prevention and treatment of dementia

Publications (1)

Publication Number Publication Date
AU2001239052A1 true AU2001239052A1 (en) 2001-09-17

Family

ID=22688461

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001239052A Abandoned AU2001239052A1 (en) 2000-03-06 2001-03-05 Compositions for prevention and treatment of dementia

Country Status (3)

Country Link
US (1) US20030144255A1 (en)
AU (1) AU2001239052A1 (en)
WO (1) WO2001066096A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
EP2138177A1 (en) 2000-03-03 2009-12-30 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments
IL150509A (en) * 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical compositions containing donepezil hydrocholoride
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2005009427A1 (en) * 2003-07-29 2005-02-03 Cell Signals Inc. Curative medicine for allergosis
RU2401125C2 (en) * 2004-12-27 2010-10-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Method of antidementia drug stabilisation
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
CA2597566A1 (en) * 2005-02-11 2006-08-17 Stephen Wills Treating microvasculature diseases with acetyl cholinesterase inhibitors
US20090131480A1 (en) * 2005-04-04 2009-05-21 Eisai Co., Ltd. Dihydropyridine Compounds for Neurodegenerative Diseases and Dementia
BRPI0608780A2 (en) * 2005-04-28 2010-11-09 Eisai R&D Man Co Ltd anti-dementia drug-containing composition
JP5379692B2 (en) 2006-11-09 2013-12-25 プロビオドルグ エージー 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5930573B2 (en) 2007-03-01 2016-06-15 プロビオドルグ エージー New use of glutaminyl cyclase inhibitors
JP2010520154A (en) * 2007-03-05 2010-06-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 AMPA receptor antagonists and NMDA receptor antagonists for neurodegenerative diseases
DK2142514T3 (en) 2007-04-18 2015-03-23 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
EP2148673A1 (en) * 2007-04-26 2010-02-03 Eisai R&D Management Co., Ltd. Cinnamide compounds for dementia
EA022007B1 (en) 2009-09-11 2015-10-30 Пробиодруг Аг Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011100373A1 (en) 2010-02-09 2011-08-18 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2542549B1 (en) 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
EA022420B1 (en) 2010-03-10 2015-12-30 Пробиодруг Аг Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (en) 2010-04-21 2016-07-05 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
WO2013063512A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
CN105142623A (en) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 Methods and compositions for improving cognitive function
EA034167B8 (en) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Extended release pharmaceutical compositions of levetiracetam
ES2812698T3 (en) 2017-09-29 2021-03-18 Probiodrug Ag Glutaminyl cyclase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532219A (en) * 1991-04-23 1996-07-02 The University Of British Columbia Dapsone and promin for the treatment of dementia
EP0642337B1 (en) * 1992-05-29 1997-09-03 University Of British Columbia Dapsone and promin for the treatment of dementia
WO1998030243A1 (en) * 1997-01-08 1998-07-16 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
WO2001066096A2 (en) 2001-09-13
US20030144255A1 (en) 2003-07-31
WO2001066096A3 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
AU2001239052A1 (en) Compositions for prevention and treatment of dementia
AUPR105400A0 (en) Processes and compositions for water treatment
WO2001078781A8 (en) Methods for prevention and treatment of gastrointestinal disorders
AU2002243023A1 (en) Compositions for preventing and/or treating oral diseases
AU2001233081A1 (en) Composition for treatment of stress
MXPA03006043A (en) Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis.
AU2002218461A1 (en) Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
AU1509999A (en) Herbal drug composition for the prevention and treatment of dementia
EP1162934A4 (en) Compositions and methods for prevention of photoaging
AU2001259817A1 (en) Methods of and compounds for inhibiting calpains
AU2001264522A1 (en) Methods and compositions for the prevention of myopia
AU2002303552A1 (en) Methods and compositions for prevention of angioproliferation
AUPR809001A0 (en) Compositions for the treatment and prevention of plant pathogens
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
AU2002364911A1 (en) Dmt-tic di- and tri-peptidic derivatives and related compositions and methods of use
AU2003301819A1 (en) Compositions and methods for prevention of photoaging
AU2002222125A1 (en) Prevention and treatment of tachyphylactic response
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2002228500A1 (en) Methods and compositions for reducing or preventing onset of milk fever
AU4034800A (en) Novel compositions and methods for prevention and treatment of protozoal disease
AU2000265105A1 (en) Methods and compositions for the prevention and treatment of syndrome x
AU2335601A (en) Treatment or prevention of diarrhea
AU2002221169A1 (en) Herbal composition for_the prevention and treatment of dementia
AU4388899A (en) Novel compositions for the treatment of atherosclerosis and related conditions